Executive Bios

Noven Directors & Officers

Directors
	WAYNE P. YETTER, Chairman Mr. Yetter serves as Noven's non-executive Chairman of the Board. He has been Chief Executive Officer of Verispan LLC (health care information) since September 2005. From November 2004 to September 2005, he served as the Chief Executive Officer of Odyssey Pharmaceuticals, Inc., the specialty pharmaceutical division of Pliva d.d. From 2003 to 2005, he served on the Advisory Board of Alterity Partners (mergers and acquisition advisory firm). From September 2000 to June 2003, Mr. Yetter served as Chairman and Chief Executive Officer of Synavant Inc. (pharmaceutical marketing/technology services). From 1999 to 2000, Mr. Yetter served as Chief Operating Officer at IMS Health, Inc. (information services for the healthcare industry). From 1997 to 1999, he served as President and Chief Executive Officer of Novartis Pharmaceuticals Corporation (pharmaceuticals). From 1991 to 1994, Mr. Yetter served as General Manager and then President of Astra Merck, a division of Merck & Co. From 1994 to 1997, he served as President and Chief Executive Officer of Astra Merck, Inc. (pharmaceuticals). Mr. Yetter serves on the board of directors of Matria Healthcare, Inc. (disease management), EpiCept Corporation (pharmaceuticals), Alteon, Inc. (pharmaceuticals) and HAPC, Inc. (healthcare acquisitions).
	PETER C. BRANDT Mr. Brandt was appointed to Noven’s board of directors and to the offices of President & Chief Executive Officer of Noven effective April 29, 2008. He spent 28 years at Pfizer, Inc., the world's leading research-based pharmaceutical company. Until early 2007, he served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he oversaw Pfizer’s U.S. pharmaceuticals organization. Previously, he led Pfizer’s Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also directed the operations of Pfizer's care management subsidiary, Pfizer Healthcare Solutions.
	SIDNEY BRAGINSKY Mr. Braginsky is President and Chief Executive Officer of Atropos Technology Inc. (consulting and venture capital) and Chairman of Digilab LLC (molecular spectroscopy). From 1970 through 1999, Mr. Braginsky served Olympus America, Inc. in a variety of roles, most recently as President and Chief Operating Officer. Mr. Braginsky serves on the board of directors of Mediscience (optical biopsy development), Diomed Holdings (laser technology), Geneva Acquisition Corporation (acquisitions) and Electro-Optical Sciences, Inc. (surgical and medical instruments).
	JOHN G. CLARKSON, M.D. Dr. Clarkson is the Executive Director of the American Board of Ophthalmology and the Dean Emeritus and Professor of Ophthalmology, Miller School of Medicine at the University of Miami. From 1995 to 2006, he served as Professor and Senior Vice President for Medical Affairs and Dean, University of Miami School of Medicine. Dr. Clarkson serves as a director of the American Board of Medical Specialties and as a trustee for the Evelyn F. McKnight Brain Research Foundation.
	DONALD A. DENKHAUS Mr. Denkhaus has, since January 2004, served as the executive chairman of TM Systems, LLC (international language services). Since 2005, he has also served as President and Chief Executive Officer of Integrity Risk Advisors (consulting). Mr. Denkhaus was a partner with Arthur Andersen LLP from 1980 to 2002 and served as Arthur Andersen’s audit practice director responsible for Florida and Puerto Rico from 1999 to 2002. For a one-year period in 2002 and 2003, Mr. Denkhaus was employed as a principal with Ernst & Young LLP where he provided audit services and assisted in the transition of Arthur Andersen audit clients and personnel to Ernst & Young.
	PEDRO P. GRANADILLO Mr. Granadillo was employed by Eli Lilly and Company (pharmaceuticals) from 1970 until 2004. From 1998 to 2004, he served as Eli Lilly’s Senior Vice President overseeing manufacturing, quality and human resources and from 1993 to 1998, he served as Vice President of Human Resources. Mr. Granadillo serves on the board of directors of First Indiana Corporation (banking), First Indiana Bank, N.A. (banking) and Haemonetics Corporation (medical devices).
	PHILLIP M. SATOW Mr. Satow was appointed to Noven’s Board of Directors in August 2007 upon the closing of Noven’s acquisition of JDS Pharmaceuticals, LLC. Mr. Satow was JDS’s co-founder and served as its Chief Executive Officer from inception in August 2004 through completion of the acquisition. After 15 years with Pfizer and three years as Vice President and General Manager of the Carter Wallace pharmaceutical business, Mr. Satow served as Executive Vice President of Forest Laboratories and President of its Forest Pharmaceuticals subsidiary. He established the marketing and sales departments at Forest, which he led for 14 years through the launch of Forest’s highly-successful antidepressant Celexa^®.
	ROBERT G. SAVAGE Mr. Savage has been the President of Strategic Imagery LLC (pharmaceutical consulting) since May 2003. He served as Group Vice President and President – General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003. From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Chairman of Johnson & Johnson’s Pharmaceutical Group. From 1985 to 1996, he served Roche Holding AG in a variety of marketing, business development and operations positions, most recently as Vice President – Marketing, Hoffmann-La Roche, Inc. Mr. Savage serves as the non-executive chairman of EpiCept Corporation (pharmaceuticals) and as the presiding director of The Medicines Company, Inc. (pharmaceuticals).

Officers
	PETER C. BRANDT Mr. Brandt was appointed to Noven’s board of directors and to the offices of President & Chief Executive Officer of Noven effective April 29, 2008. He spent 28 years at Pfizer, Inc., the world's leading research-based pharmaceutical company. Until early 2007, he served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he oversaw Pfizer’s U.S. pharmaceuticals organization. Previously, he led Pfizer’s Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also directed the operations of Pfizer's care management subsidiary, Pfizer Healthcare Solutions.
	JEFFREY F. EISENBERG Mr. Eisenberg serves as Noven’s Executive Vice President. He has been part of Noven’s senior management team since 1998, having served as Senior Vice President – Strategic Alliances, and as General Counsel. From 1995 through 1998, he served as Associate General Counsel and then as Acting General Counsel of IVAX Corporation. Prior to IVAX, he was a lawyer in the corporate securities department of the law firm of Steel Hector & Davis.
	MICHAEL D. PRICE Michael Price joined Noven in November 2007 and serves as Vice President and Chief Financial Officer. He is a CPA with over 25 years of experience as a financial executive. From 1992 to 2006, he served as vice president, chief financial officer, treasurer and secretary for Bentley Pharmaceuticals, Inc., a NYSE listed specialty pharmaceuticals company. He also acted as a member of that company’s board of directors for nine years. Earlier in his career, he served as a senior executive with Carr Financial Group, and as vice president - finance with Premiere Group, Inc.
	STEVEN M. DINH Mr. Dinh joined Noven in June 2008 and serves as Vice President and Chief Scientific Officer. He has more than 25 years' experience in drug delivery, biotechnology, pharmaceutical development and polymer engineering. Prior to joining Noven, he served as Vice President of Research and Technology Development and Co-Chair – Office of the President for Emisphere Technologies. Earlier, he served as Chief Scientific Officer and Vice President of Research & Development for Lavipharm Laboratories, and before that, he held several senior-level R&D positions at Novartis Pharmaceuticals Corporation and Ciba-Geigy. Mr. Dinh has co-authored three books, over 30 articles for scientific publications, and more than 100 abstracts. He holds a Doctor of Science degree from the Massachusetts Institute of Technology, a Masters of Science degree from Cornell University, and a Bachelor of Engineering degree from Cooper Union.
	CAROLYN DONALDSON Carolyn Donaldson has been with Noven since June 1998 and serves as Vice President – Human Resources. Prior to joining Noven, she served as Vice President of Human Resources for IVAX Corporation, a global branded and generic pharmaceutical company. From 1984 to 1997 she served as Executive Director – Human Resources at Cordis Corporation.
	RICHARD P. GILBERT Richard Gilbert joined Noven in December 2004 and serves as Vice President – Operations. He has over 22 years of experience in operations and manufacturing. Prior to joining Noven, he served as Vice President, Manufacturing Operations, at ConvaTec (a Bristol-Myers Squibb Company). Prior to ConvaTec, he held various senior roles at London International Group, LLC, The Tensar Corporation, and Richmond Technology.
	PAVAN HANDA Pavan Handa joined Noven in July 2002 and serves as Vice President – Business Development. He has over fifteen years of pharmaceutical industry experience in structuring and negotiating numerous agreements involving licensing, acquisitions, and strategic collaborations. Prior to joining Noven, he served as Senior Vice President, Business Development and Portfolio Management for Pharmacologics LLC, Director of Business Development and Marketing for Enzon Pharmaceuticals Inc., and Manager of Biomedical Business Development for Union Carbide Corporation.
	JOSEPH C. JONES Joseph Jones has been with Noven since January 2001 and serves as Vice President – Corporate Affairs. He is principally responsible for analyst, investor and corporate communications as well as the company's governmental affairs function. Prior to joining Noven, he was President of SHD Strategic, L.C., a corporate communications consulting firm, and before that he served as Vice President, Investor Relations and Government Affairs for IVAX Corporation. Prior to joining IVAX, he was a partner in the corporate securities department of the law firm of Steel Hector & Davis.
	JOEL S. LIPPMAN, M.D. Dr. Lippman joined Noven in July 2008 as Vice President – Clinical Development & Chief Medical Officer. Dr. Lippman is an obstetrician-gynecologist certified by the American Board of Obstetrics and Gynecology with nearly 20 years of clinical development and medical affairs experience in the pharmaceutical and device industries. Prior to joining Noven, Dr. Lippman served as Worldwide Vice President – Medical Affairs & Chief Medical Officer and as a member of the Global Management Board at Ethicon, Inc., a Johnson & Johnson company. Earlier, he served as Vice President – Clinical Trials at Ortho-McNeil Pharmaceutical, Inc., also a Johnson & Johnson company, and before that, he served in a number of clinical development, medical affairs and related roles at Wyeth-Ayerst Laboratories. Dr. Lippman holds a Medical Degree from New York Medical College and a Masters in Public Health from Harvard University School of Public Health, and is a Fellow of the American College of Obstetricians and Gynecologists.
	JUAN A. MANTELLE Juan Mantelle has been with Noven since March 1990 and, since June 2000, has served as Vice President and Chief Technical Officer. From December 1986 to March 1990, he served Paco Research Corp. as Manager – Product Development. From April 1983 to December 1986, he served Key Pharmaceuticals, Inc. as Senior Research Engineer where he helped develop some of the most successful transdermal products of that era.
	JEFF T. MIHM Jeff Mihm has been with Noven since 2003 and serves as Vice President and General Counsel. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., the world's third largest Coca-Cola bottler at the time, and previously was a partner in the corporate securities department of the law firm of Steel Hector & Davis.
	ANTHONY VENDITTI Mr. Venditti joined Noven in June 2008 and serves as Vice President – Marketing & Sales. He has over 20 years of pharmaceutical marketing and sales experience. Prior to joining Noven, he served as Vice President and head of the U.S. Neuroscience division for Novartis Pharmaceuticals Corporation, where he was responsible for marketing, sales and new product operations for the central nervous system (CNS) portfolio in the U.S. Before that, he served Novartis in a number of senior executive positions, with responsibility for marketing, sales, business analysis, strategic planning and new product commercialization, including key roles in the launch of several new products.